Curative Biosciences, Inc.
CBDX
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 547.93% | 508.22% | -96.28% | -96.84% | -95.27% |
| Depreciation & Amortization | 0.00% | -33.33% | -50.00% | -33.33% | -33.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 538.84% | 494.78% | -96.14% | -96.76% | -95.20% |
| Operating Income | -538.84% | -494.78% | 96.14% | 96.76% | 95.20% |
| Income Before Tax | -538.84% | -494.78% | 96.14% | 96.79% | 95.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -538.84% | -494.78% | 96.14% | 96.79% | 95.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -538.84% | -494.78% | 96.14% | 96.79% | 95.74% |
| EBIT | -538.84% | -494.78% | 96.14% | 96.76% | 95.20% |
| EBITDA | -558.37% | -512.19% | 96.37% | 96.92% | 95.35% |
| EPS Basic | -513.46% | -488.46% | 96.75% | 97.41% | 96.63% |
| Normalized Basic EPS | -503.03% | -478.79% | 96.59% | 97.29% | 96.09% |
| EPS Diluted | -513.46% | -488.46% | 96.75% | 97.41% | 96.63% |
| Normalized Diluted EPS | -503.03% | -478.79% | 96.59% | 97.29% | 96.09% |
| Average Basic Shares Outstanding | 7.06% | 1.14% | 4.98% | 12.72% | 21.61% |
| Average Diluted Shares Outstanding | 7.06% | 1.14% | 4.98% | 12.72% | 21.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |